Format
Sort by
Items per page

Send to

Choose Destination

Best matches for CLOBETASOL/PD:

Search results

Items: 1 to 20 of 812

1.

Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis

Stein Gold L, Bagel J, Lebwohl M, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2018 Dec 1;17(12):1290-1296.

PMID:
30586261
2.

Granuloma annulare on the palms in an elderly patient.

Mello DS, Fernandes MRN, Gripp AC, Alves MFGS.

An Bras Dermatol. 2018 Nov/Dec;93(6):878-880. doi: 10.1590/abd1806-4841.20187385.

3.

Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.

Green LJ, Kerdel FA, Cook-Bolden FE, Bagel J, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Drugs Dermatol. 2018 Oct 1;17(10):1062-1069.

PMID:
30365586
4.

Cushing Syndrome Induced by Topical Corticosteroids for the Treatment of Lichen Sclerosus.

Notay M, Fazel N, Awasthi S.

J Pediatr Adolesc Gynecol. 2019 Feb;32(1):83-85. doi: 10.1016/j.jpag.2018.09.004. Epub 2018 Sep 20.

PMID:
30244192
5.

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.

Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R.

J Drugs Dermatol. 2018 Aug 1;17(8):863-868.

PMID:
30124725
6.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R.

J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

PMID:
30124724
7.

Paraneoplastic granulomatous dermatitis in a patient with Hodgkin's disease: a diagnostic pitfall.

Tabata MM, Novoa RA, Martires KJ.

BMJ Case Rep. 2018 Aug 11;2018. pii: bcr-2018-224961. doi: 10.1136/bcr-2018-224961.

PMID:
30100570
8.
10.

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.

Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R.

J Drugs Dermatol. 2018 Jul 1;17(7):723-726.

PMID:
30005093
11.

Tamsulosin-induced photosensitivity rash.

Tan CK, Yap KB.

Singapore Med J. 2018 Jun;59(6):336-337. doi: 10.11622/smedj.2018072. No abstract available.

12.

In vitro penetration through the skin layers of topically applied glucocorticoids.

Carrer V, Alonso C, Oliver MA, Coderch L.

Drug Test Anal. 2018 Oct;10(10):1528-1535. doi: 10.1002/dta.2412. Epub 2018 Jun 20.

PMID:
29788546
13.

[Topical application of clobetasol propionate cream in the treatment of phimosis in prepubertal children: A report of 237cases].

Wen YL, Wang AG, Zhang ZP, Wu J, Jiang T.

Zhonghua Nan Ke Xue. 2017 Jul;23(7):635-638. Chinese.

PMID:
29723458
14.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.

Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Am Acad Dermatol. 2018 Aug;79(2):287-293. doi: 10.1016/j.jaad.2018.03.040. Epub 2018 Apr 1.

16.

Low systemic exposure and calcemic effect of calcipotriol/betamethasone ointment in rats with imiquimod-induced psoriasis-like dermatitis.

Satake K, Amano T, Okamoto T.

Eur J Pharmacol. 2018 May 5;826:31-38. doi: 10.1016/j.ejphar.2018.02.032. Epub 2018 Feb 21.

17.

Silicone elastomer blends: A novel topical drug delivery platform.

Aliyar HA, Huber RO, Loubert GL, Schalau GK, Maxon BD.

J Cosmet Sci. 2017 Jan/Feb;68(1):74-78. No abstract available.

PMID:
29465386
18.

Man With Bumps on His Shin.

Green WL, Roppolo LP.

Ann Emerg Med. 2018 Feb;71(2):168-182. doi: 10.1016/j.annemergmed.2017.07.490. Epub 2018 Feb 5. No abstract available.

PMID:
29447859
19.

Exogenous Cushing syndrome due to misuse of potent topical steroid.

Özgüç Çömlek F, Örüm S, Aydın S, Tütüncüler F.

Pediatr Dermatol. 2018 Mar;35(2):e121-e123. doi: 10.1111/pde.13409. Epub 2018 Jan 9.

PMID:
29315782
20.

Randomized, placebo-controlled, double-blind trial of clobetasol propionate 0.05% in the treatment of oral lichen planus.

Arduino PG, Campolongo MG, Sciannameo V, Conrotto D, Gambino A, Cabras M, Ricceri F, Carossa S, Broccoletti R, Carbone M.

Oral Dis. 2018 Jul;24(5):772-777. doi: 10.1111/odi.12821. Epub 2018 Mar 13.

Supplemental Content

Loading ...
Support Center